|
Name |
C19-gibberellin skeleton
|
Molecular Formula | C19H23O4- | |
IUPAC Name* |
(1R,2R,5R,8R,9S,10R,11S)-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
|
|
SMILES |
C[C@]12CCC[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@H](C4)C(=C)C5)C(=O)[O-])OC2=O
|
|
InChI |
InChI=1S/C19H24O4/c1-10-8-18-9-11(10)4-5-12(18)19-7-3-6-17(2,16(22)23-19)14(19)13(18)15(20)21/h11-14H,1,3-9H2,2H3,(H,20,21)/p-1/t11-,12-,13-,14-,17+,18+,19-/m1/s1
|
|
InChIKey |
MHVYWTXXZIFXDT-PKZSZHAESA-M
|
|
Synonyms |
C19 skeleton; C19-GA skeleton; C19-gibberellin skeleton; C19-GAs; closed lactone gibberellin skeleton; GA9
|
|
CAS | NA | |
PubChem CID | 25244370 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 315.4 | ALogp: | 3.3 |
HBD: | 0 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.4 | Aromatic Rings: | 5 |
Heavy Atoms: | 23 | QED Weighted: | 0.55 |
Caco-2 Permeability: | -5.531 | MDCK Permeability: | 0.00001110 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.332 |
30% Bioavailability (F30%): | 0.277 |
Blood-Brain-Barrier Penetration (BBB): | 0.44 | Plasma Protein Binding (PPB): | 73.99% |
Volume Distribution (VD): | 0.307 | Fu: | 14.98% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.411 |
CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.654 |
CYP2C9-inhibitor: | 0.025 | CYP2C9-substrate: | 0.352 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.183 |
CYP3A4-inhibitor: | 0.189 | CYP3A4-substrate: | 0.085 |
Clearance (CL): | 4.717 | Half-life (T1/2): | 0.56 |
hERG Blockers: | 0.147 | Human Hepatotoxicity (H-HT): | 0.948 |
Drug-inuced Liver Injury (DILI): | 0.735 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.617 | Maximum Recommended Daily Dose: | 0.653 |
Skin Sensitization: | 0.223 | Carcinogencity: | 0.209 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.032 |
Respiratory Toxicity: | 0.935 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002541 | 0.667 | D0KR5B | 0.274 | ||||
ENC002558 | 0.630 | D0I2SD | 0.269 | ||||
ENC002556 | 0.613 | D07BSQ | 0.267 | ||||
ENC000794 | 0.605 | D0IX6I | 0.262 | ||||
ENC002559 | 0.590 | D0EP0C | 0.261 | ||||
ENC002554 | 0.566 | D0F1UL | 0.255 | ||||
ENC002542 | 0.517 | D0I1LH | 0.248 | ||||
ENC003145 | 0.379 | D0R7JT | 0.245 | ||||
ENC003679 | 0.337 | D04GJN | 0.245 | ||||
ENC002007 | 0.337 | D04SFH | 0.245 |